OnabotulinumtoxinA (Botox) showed a sustained reduction in headache-day frequency and significant improvement in quality-of-life measures in patients with chronic migraine followed for 2 years, according to a recent study looking at real-world effects.
Real-world preventive treatment of chronic migraine with onabotulinumtoxinA (Botox) showed a sustained reduction in headache-day frequency and significant improvement in quality-of-life measures, according to a recent study looking at results over 2 years.
In the REPOSE study (REal-life use of botulinum toxin for the symptomatic treatment of adults with chronic migraine, measuring healthcare resource utilization, and Patient-reported OutcomeS observed in practice), patients received an injection every 12 weeks. The study was a European, open-label, multicenter, prospective, noninterventional study.
Of 641 patients enrolled, 633 received at least 1 dose of onabotulinumtoxinA for a total of 3499 treatment sessions. At baseline, mean (SD) age was 45.4 (11.7) years; most patients were women (85.3%). Injection practices closely followed the packaging insert in mean dosage (155.1 U) and injection sites per session (31.4), with the exception of a prolongation of the recommended 12-week dosing interval, with 79.1% of patients receiving at least 1 treatment session that was more than 13 weeks after the previous treatment session.
Headache-day frequency was reduced from a baseline mean (SD) of 20.6 (5.4) days to 7.4 (6.6) days at administration visit 8 (P <.001). Each domain on the Migraine-Specific Quality-of-Life Questionnaire—restrictive, preventive, and emotional—was significantly reduced from baseline through each administration visit (P <.001).
In addition, the median EuroQol 5-Dimension Questionnaire total and health state scores were significantly improved from baseline through each administration visit (P <.001).
Overall, 18.3% of patients reported an adverse drug reaction (ADR). Most ADRs were mild to moderate, with only 1.3% of patients reporting a serious ADR. Eyelid ptosis (5.4%), neck pain (2.8%), and musculoskeletal stiffness (2.7%) were the most frequently reported ADRs.
No new safety concerns were identified.
Other preventative treatments for migraine include calcitonin gene-related peptide inhibitors. Earlier this year, the American Headache Society noted that Botox does not require a gradual dose escalation for injectable use and has a rapid onset of benefits.
Reference
Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study [published online March 7, 2019]. J Headache Pain. doi: 10.1186/s10194-019-0976-1.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen